Skip to main content
Department of Pharmaceutical Organic Chemistry

Research

Our researches Plan:

1- Development, study in depth of pharmaceutical organic chemistry and illustration of its synthetic, mechanistic, and industrial applications.

2- Design and synthesis of different classes of compounds such as: Triazoles, benzimidazoles, piperazinedione and thiadiazine derivatives and others A special focus on xanthine and pyridazinone derivatives

3- Structural elucidation of the target compounds utilizing: IR,1H-NMR, MS in addition to elemental analysis Optical Rotation

4- Biological screening: Antimicrobial: antibacterial, antifungal and antituberculosis in addition to anthlemintic activity. Anti-inflammatory, analgesic, antipyretic activities and ulcerogenicity determination. Cardiotonic and hypotensive activities. Hypoglycemic activity. Anticonvulsant activity.

5- Other titles in consideration: Synthesis of new dendimers of potential biological activity. Applications of photochemical reactions for synthesis of certain organic compounds of potential biological activity. Synthesis of some antineurodegenerative compounds. Synthesis of certain nucleosides of potential biological activity. Synthesis of certain adenine derivatives of possible antiviral activity.

# Title Research Year
51 Design, synthesis and antiproliferative evaluation of lipidated 1, 3-diaryl propenones and their cyclized pyrimidine derivatives as tubulin polymerization inhibitors‏ 2023
52 Novel fluoroquinolone hybrids as dual DNA gyrase and urease inhibitors with potential antibacterial activity: Design, synthesis, and biological evaluation 2023
53 Discovery and optimization of 2,3-diaryl-1,3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity 2023
54 New 1,2,3-Triazole/1,2,4-triazole Hybrids as Aromatase Inhibitors: Design, Synthesis, and Apoptotic Antiproliferative Activity 2023
55 New 1, 3, 4‐oxadiazoles linked with the 1, 2, 3‐triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase 2022
56 New 1,3,4-Oxadiazole-Chalcone/Benzimidazole Hybrids as Potent Anti-proliferative Agents 2022
57 The inhibitory coreceptor CD22 restores B cell signaling by developmentally regulating Cd45 −/− immunodeficient B cells 2022
58 Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAFV600E with promising antiproliferative properties 2022
59 Novel piperine-carboximidamide hybrids: design, synthesis, and antiproliferative activity via a multi-targeted inhibitory pathway 2022
60 Novel indazole derivatives as potent apoptotic antiproliferative agents by multi-targeted mechanism: Synthesis and biological evaluation 2022